Literature DB >> 7600302

A unique tumor antigen produced by a single amino acid substitution.

P A Monach1, S C Meredith, C T Siegel, H Schreiber.   

Abstract

Mice immunized against a cancer recognize antigens unique to that cancer, but the molecular structures of such antigens are unknown. We isolated CD4+ T cell clones recognizing an antigen uniquely expressed on the UV-induced tumor 6132A; some clones inhibited the growth of tumors bearing the specific antigen. A T cell hybridoma was used to purify this antigen from nuclear extracts by RP-HPLC and SDS-PAGE using T cell immunoblot assays. A partial amino acid sequence was nearly identical to a sequence in ribosomal protein L9. The cDNA sequence of L9 from 6132A PRO cells differed from the normal sequence at one nucleotide; this mutation encoded histidine instead of leucine at position 47. A synthetic peptide containing this mutation was over 1000-fold more stimulatory of T cells than was the wild-type peptide. These results indicate that this unique tumor antigen is derived from a single amino acid substitution in a cellular protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600302     DOI: 10.1016/1074-7613(95)90078-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  87 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors:  S Basu; P K Srivastava
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

3.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

4.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 5.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

Review 6.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 7.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 8.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

Review 9.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.